Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

Lab-Grown Neocortex Models Mimic Early Brain Organization

Published

on

During brain development, distinct areas emerge that take on different jobs including movement, vision, memory, and language. At this stage of development, chemical signals help tell developing cells where they are, contributing to differences between areas at the front and the back of the cerebral cortex. This process, dubbed arealization by scientists, is believed to underpin much of the brain’s activity and may help explain what occurs in some brain disorders. 

To date, this type of organization has been difficult to reproduce in lab-grown models of the human brain. But now, scientists at the University of California (UC), Irvine, have developed a new approach that lets them engineer lab-grown human brain tissue with a defined regional identity. The result is brain organoids with characteristics of either the front or back of the developing cerebral cortex that could be used in studies of how neurodevelopmental disorders develop. Full details are provided in a Cell Stem Cell paper titled “Morphogen-guided neocortical organoids with anteroposterior areal identity.”

According to the paper, the UC Irvine team used the approach to generate neocortical organoids from human stem cells that copy important features of the developing cerebral cortex. Each organoid was steered to take on the identity of either a front or back region using carefully selected chemical signals. It is an important step, one that ordinary organoids lack. Without this step, organoids end up with a patchwork of random regions rather than a clear front or back. 

In this study, after exposing the organoids to the chemical signals, the scientists examined the individual cells to determine whether those differences resembled actual human development. Their analysis of more than 200,000 cells showed that the organoids reproduced molecular characteristics that were associated with different regions of the prenatal human context. 

As an example of how these organoids can be used, the scientists used their new model to investigate fragile X syndrome. They wanted to know whether this genetic condition might affect both individual brain cells and broader developmental patterns that help organize those cells across the cortex.

Specifically, they looked at two proteins important to brain development, SOX4 and SOX11, that normally appear at different levels in front and back tissue. That difference showed up reliably in organoids grown from donors without the condition. In organoids modeling fragile X syndrome, it largely disappeared. The broad front-to-back patterning was still there, but this particular difference had flattened out.

This finding is supported by other research in donated tissue from people with autism. Importantly, the findings do not show that disrupted brain patterning causes autism. Instead, they highlight a potential developmental process that researchers can now investigate in a human tissue model with greater spatial detail.

These more fine-grained models could also be used in other types of studies, according to the scientists. Neurological and neurodevelopmental disorders do not necessarily affect every part of the brain in the same way. So by giving organoids defined regional characteristics, researchers can begin studying not only what changes in a disorder but also where those changes emerge during development.

Furthermore, the platform contributes to growing efforts to develop human tissue-based research models that can complement animal studies. The scientists believe that the approach could be used to examine how genetic and environmental factors affect different regions of the developing cortex and, over time.

The post Lab-Grown Neocortex Models Mimic Early Brain Organization appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New webinar: Tackling drug discovery challenges in cancer research

Published

on

Cancer cells

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.

You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.

Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.

Q&A with the speakers follows the presentations.

Register for free now.

The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).

Continue Reading

Uncategorized

Psilocybin proves promising in neuropathic pain mouse study

Published

on

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.

Continue Reading

Uncategorized

New Spectrometry Technique Could Aid Formulation Development

New Spectrometry Technique Could Aid Formulation Development

Published

on

A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.

According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.

“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”

Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.

The challenge is understanding the link between these things within a heterogeneous sample, he says.

To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.

He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.

Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.

Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read